AI Summary & Key Takeaways
AI InsightConclusion: In our study, a significant improvement in detectable HBV DNA, ALT level, and phosphorus level was observed in both naive and treatment-experienced patients with the initiation of TAF.
📌 3 Key Takeaways
Abstract
Aims: Chronic hepatitis B virus (CHB) infection causes chronic liver disease, cirrhosis, and hepatocellular carcinoma. Our study aimed to evaluate the effects of newly initiated tenofovir alafenamide fumarate (TAF) on clinical parameters in naïve and treatment-experienced patients with CHB. Methods: This retrospective, single-center observational study was performed in the Department of Infectious Diseases and Clinical Microbiology, Kayseri City Hospital. Demographic and clinical characteristics of the cases were obtained from the outpatient clinic follow-up files. The change over time in the clinical data of all patients at the beginning, 3rd, 6th, and 12th months of TAF treatment was evaluated using One-Way Analysis of Variance in Repeated Measures (ANOVA) and Friedman Analysis of Variance in Repeated Measures, according to their compliance with normal distribution. Results: The mean age of the patients was 56.5±12.2 years, and 59 (57.8%) were male. 70.6% of the patients had at least one additional disease, and the most common additional diseases were hypertension (29.4%) and Diabetes mellitus (23.5%). Of the 102 patients who started TAF treatment, 81 (79.4%) were treatment-experienced, and 21 (20.6%) were treatment-naïve patients. The reasons for switching to TAF treatment were osteoporosis (44.1%), the need for a more potent agent (34.3%), and low GFR (13.7). While the detectable HBV DNA rate was 38.2% at the beginning of treatment, this rate was 2.9% at the 12th month (p<0.001). While there was a statistically significant change in ALT, abnormal ALT, and detectable HBV DNA rates from all four follow-up periods within 12 months after the start of TAF treatment (p values <0.001), there was no significant change in AST (p=0.081). While the GFR level did not change statistically significantly during the follow-up period (p=0.381), the phosphorus level changed statistically significantly (p-value<0.001). Conclusion: In our study, a significant improvement in detectable HBV DNA, ALT level, and phosphorus level was observed in both naive and treatment-experienced patients with the initiation of TAF.
Özet
Aim: Chronic hepatitis B virus (CHB) infection causes chronic liver disease, cirrhosis, and hepatocellular carcinoma. Our study aimed to evaluate the effects of newly initiated tenofovir alafenamide fumarate (TAF) on clinical parameters in naïve and treatment-experienced patients with CHB. Material and Method: This retrospective, single-center observational study was performed in the Department of Infectious Diseases and Clinical Microbiology, XXX City Hospital. Demographic and clinical characteristics of the cases were obtained from the outpatient clinic follow-up files. The change over time in the clinical data of all patients at the beginning, 3rd, 6th, and 12th months of TAF treatment was evaluated using One-Way Analysis of Variance in Repeated Measures (ANOVA) and Friedman Analysis of Variance in Repeated Measures, according to their compliance with normal distribution. Results: The mean age of the patients was 56.5± 12.2 years, and 59 (57.8%) were male. 70.6% of the patients had at least one additional disease, and the most common additional diseases were hypertension (29.4%) and Diabetes mellitus (23.5%). Of the 102 patients who started TAF treatment, 81 (79.4%) were treatment-experienced, and 21 (20.6%) were treatment-naïve patients. The reasons for switching to TAF treatment were osteoporosis (44.1%), the need for a more potent agent (34.3%), and low GFR (13.7). While the detectable HBV DNA rate was 38.2% at the beginning of treatment, this rate was 2.9% at the 12th month (p=<0.001). While there was a statistically significant change in ALT, abnormal ALT, and detectable HBV DNA rates from all four follow-up periods within 12 months after the start of TAF treatment (p values <0.001), there was no significant change in AST (p = 0.081). While the GFR level did not change statistically significantly during the follow-up period (p = 0.381), the phosphorus level changed statistically significantly (p-value = <0.001). Conclusion: In our study, a significant improvement in detectable HBV DNA, ALT level, and phosphorus level was observed in both naïve and treatment-experienced patients with the initiation of TAF.